These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 17925895

  • 1. Neurodegenerative disorders and their treatment.
    Karran E, Palmer AM.
    Drug News Perspect; 2007; 20(6):407-12. PubMed ID: 17925895
    [Abstract] [Full Text] [Related]

  • 2. Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
    Morimoto B.
    IDrugs; 2010 Jul; 13(7):440-3. PubMed ID: 20582866
    [Abstract] [Full Text] [Related]

  • 3. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.
    Almeida-Santos AF, Kangussu LM, Campagnole-Santos MJ.
    Protein Pept Lett; 2017 Nov 17; 24(9):841-853. PubMed ID: 28828974
    [Abstract] [Full Text] [Related]

  • 4. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF, Chern Y.
    Handb Exp Pharmacol; 2011 Nov 17; (200):267-310. PubMed ID: 20859800
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
    Bansal R, Singh R.
    Med Res Rev; 2018 Jul 17; 38(4):1126-1158. PubMed ID: 28697282
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
    Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T, Yong VW.
    J Neuroimmunol; 2006 Jul 17; 176(1-2):198-215. PubMed ID: 16983747
    [Abstract] [Full Text] [Related]

  • 9. Benefits of curcumin in brain disorders.
    Bhat A, Mahalakshmi AM, Ray B, Tuladhar S, Hediyal TA, Manthiannem E, Padamati J, Chandra R, Chidambaram SB, Sakharkar MK.
    Biofactors; 2019 Sep 17; 45(5):666-689. PubMed ID: 31185140
    [Abstract] [Full Text] [Related]

  • 10. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients.
    Simpkins JW, Gatson JW, Wigginton JG.
    Alzheimers Dement; 2009 Mar 17; 5(2):143-6. PubMed ID: 19328446
    [No Abstract] [Full Text] [Related]

  • 11. The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies.
    Mines M, Ding Y, Fan GH.
    Curr Med Chem; 2007 Mar 17; 14(23):2456-70. PubMed ID: 17979699
    [Abstract] [Full Text] [Related]

  • 12. Society for Neuroscience--38th Annual Meeting--Therapeutics for Parkinson's disease.
    Gotham S.
    IDrugs; 2009 Jan 17; 12(1):10-1. PubMed ID: 19127496
    [No Abstract] [Full Text] [Related]

  • 13. Gene discovery and validation for neurodegenerative diseases.
    Mathisen PM.
    Drug Discov Today; 2003 Jan 01; 8(1):39-46. PubMed ID: 12546990
    [Abstract] [Full Text] [Related]

  • 14. Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.
    Clark IA, Vissel B.
    J Alzheimers Dis; 2021 Jan 01; 79(3):931-948. PubMed ID: 33459706
    [Abstract] [Full Text] [Related]

  • 15. Cerium oxide nanoparticles: a 'radical' approach to neurodegenerative disease treatment.
    Naz S, Beach J, Heckert B, Tummala T, Pashchenko O, Banerjee T, Santra S.
    Nanomedicine (Lond); 2017 Mar 01; 12(5):545-553. PubMed ID: 28181459
    [Abstract] [Full Text] [Related]

  • 16. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A, Kirkham K, Hookes L.
    IDrugs; 2009 Dec 01; 12(12):734-7. PubMed ID: 19943211
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide and neurological disorders.
    Duncan AJ, Heales SJ.
    Mol Aspects Med; 2005 Dec 01; 26(1-2):67-96. PubMed ID: 15722115
    [Abstract] [Full Text] [Related]

  • 18. Management of neurodegenerative disorders.
    Hosp Med; 1999 Jul 01; 60(7):509-15. PubMed ID: 10605544
    [Abstract] [Full Text] [Related]

  • 19. Mitophagy in neurodegeneration: an opportunity for therapy?
    Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.
    Curr Drug Targets; 2011 Jun 01; 12(6):790-9. PubMed ID: 21269269
    [Abstract] [Full Text] [Related]

  • 20. Cerebral vasomotor reactivity in neurodegenerative diseases.
    Smoliński Ł, Członkowska A.
    Neurol Neurochir Pol; 2016 Jun 01; 50(6):455-462. PubMed ID: 27553189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.